Lates News

According to Every AI Express, Pacific Securities issued a research report on November 5th giving a "buy" rating to Kangchen Pharmaceutical (603590.SH). The main reasons for the rating include: 1) Marketing transformation and indication expansion improve the market space for thrombin; 2) The innovative drug pipeline is progressing smoothly, actively laying out more pipelines. (Daily Economic News)